US FDA approves Novartis Kesimpta (ofatumumab) for relapsing forms of MS treatment EP News Bureau Aug 21, 2020 Ofatumumab was first approved by the FDA in 2009 for the treatment of chronic lymphocytic leukaemia (CLL)
Novartis acquires all remaining rights to GSK’s Ofatumumab Usha Sharma Aug 21, 2015 To develop treatments for MS and other autoimmune indications
